ScreenerHero

HRTISHerantis Pharma Oyj

HEL · FI · Healthcare · Biotechnology · herantis.com
1.532EUR+0.13%Mkt Cap: 44.13M $P/E: —

Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead p…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap44.13M $
Enterprise Value40.35M $
Revenue (TTM)-146.74K $
Gross Profit-146.74K $
Net Income (TTM)-7.20M $
Revenue/Share-0.0054 USD
Last Price1.532 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees14
CountryFI
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.51
PEG—
EV/EBITDA—
EV/Revenue-274.95
P/S-300.77
P/B-51.07
EPS (TTM)-0.27
EPS (Forward)-0.18
52W Range
1.4404% of range3.870
52W High3.870 EUR
52W Low1.440 EUR
Profitability
Gross Margin0.00%
Oper. Margin4817.53%
EBITDA Margin0.00%
Profit Margin0.00%
ROE392.28%
ROA-248.09%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.63M $
CapEx (TTM)—
FCF Margin2429.48%
FCF Yield-8.08%
Net Debt-3.79M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.01
Current Ratio2.89
Quick Ratio2.60
Book Value/Sh-0.0300 EUR
Cash/Share0.1320 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)2.000 EUR
Upside (mean)+30.5%
Target Range2.000 EUR – 2.000 EUR
# Analysts1
Ownership
Shares Out.26.50M
Float15.67M
Insiders24.99%
Institutions24.49%
Technical
SMA 501.725 (-11.2%)
SMA 2001.939 (-21.0%)
Beta0.60
S&P 52W Chg19.18%
Avg Vol (30d)33.06K
Avg Vol (10d)44.94K
Technical Indicators
RSI (14)39.6
MACD-0.0205
MACD Signal-0.0210
MACD Hist.+0.0005
BB Upper1.786 EUR
BB Middle1.620 EUR
BB Lower1.453 EUR
BB Width20.57%
ATR (14)0.1049 EUR
Vol Ratio (20d)1.74x